Biosite Diagnostics, Inc.

Biosite Incorporated

Other

Novartis Ag

Medarex Inc.

Gunars E Valkirs

Kenneth Francis Buechler

Joe Buechler

Jeff Gray

Richard R Anderson

Howard J Kirchick

Jeffrey R Dahlen

Nils Lonberg

Emma Michelle Campbell

Sofia Parveen

Bruce Andrew Lee

Theodore T Lee

Mark R Nowakowski

Becky Mar Flores

Byron J Knight

Uday Kumar Veeramallu

Joseph Buechler

Matt McDermott

Brian Wayne Chambers

Seok-Won Lee

Adam Sampson

Shanthi Govindaraj

Richard Ray Anderson

The present invention relates to human anti-IL-13 binding molecules, particularly antibodies, and to methods for using anti-IL-13 antibody molecules in diagnosis or treatment of IL-13 related disorders, such as asthma, atopic dermatitis, allergic rhinitis, fibrosis, inflammatory bowel disease and Hodgkin's lymphoma.

Nucleic acid encoding anti-IL13 human antibodies

Methods of using anti-IL13 human antibodies

Method of using anti-IL-13 antibodies

Anti-IL13 human antibodies

The present invention relates to methods and compositions for measuring latent protein C in test samples, particularly patient samples. The methods and compositions described are sensitive for latent protein C, relative to activated protein C.

Latent protein C assays and their uses for diagnosis and/or prognosis in systemic inflammatory response syndromes

The present invention relates to materials and procedures for evaluating the prognosis of patients suffering from acute coronary syndromes. In particular, the level of BNP, or a marker related to BNP, in a patient sample, alone or in combination with one or more other prognostic markers, provides prognostic information useful for predicting near-term morbidity and/or mortality across the entire spectrum of acute coronary syndromes, including unstable angina, non-ST-elevation non-Q wave myocardial infarction, ST-elevation non-Q wave MI, and transmural (Q-wave) MI.

Use of B-type natriuretic peptide as a prognostic indicator in acute coronary syndromes

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

Diagnostic markers of stroke and cerebral injury and methods of use thereof

The present invention relates to methods for the diagnosis and evaluation of stroke and transient ischemic attacks. In a particular aspect, patient samples are analyzed for the presence or amount of a panel of markers comprising one or more specific markers for cerebral injury and one or more non-specific markers for cerebral injury. In an alternative aspect, samples are analyzed for B-type natriuretic peptide. A variety of markers are disclosed for assembling a panel for such diagnosis and evaluation. In various aspects, the invention provides methods for early detection and differentiation of stroke types and transient ischemic attacks, for determining the prognosis of a patient presenting with stroke symptoms, and identifying a patient at risk for cerebral vasospasm. Invention methods provide rapid, sensitive and specific assays to greatly increase the number of patients that can receive beneficial stroke treatment and therapy, and reduce the costs associated with incorrect stroke diagnosis.

This invention pertains to methods for detectingand antibodies to, the causative agent of anthrax, in a subject.

[object Object]

The present invention relates to methods for the diagnosis and evaluation of acute coronary syndromes. In particular, patient test samples are analyzed for the presence and amount of members of a panel of markers comprising one or more specific markers for myocardial injury and one or more non-specific markers for myocardial injury. A variety of markers are disclosed for assembling a panel of markers for such diagnosis and evaluation. In various aspects, the invention provides methods for the early detection and differentiation of stable angina, unstable angina, and myocardial infarction. Invention methods provide rapid, sensitive and specific assays that can greatly increase the number of patients that can receive beneficial treatment and therapy, reduce the costs associated with incorrect diagnosis, and provide important information about the prognosis of the patient.

Diagnostic markers of acute coronary syndrome and methods of use thereof

This invention provides novel methods, reagents, and kits that are useful for detecting. The methods are based on the discovery of binding agents, including recombinant polyclonal antibodies, which bind to the surface array protein of

The invention provides in vitro methods of detection using human antibodies. The methods are particularly useful for analyzing human samples containing HAMA or heterophilic antibodies. A human antibody can bind to an analyte in such samples without binding to HAMA or heterophilic antibodies present in the samples. The methods can be effected using a sandwich format among others.

Human antibodies as detection reagents

The invention uses the power of display selection methods to screen libraries of human immunoglobulin genes from nonhuman transgenic animals expressing human immunoglobulins. Such screening produces unlimited numbers of high affinity human antibodies to any target of interest.

Growing community of inventors

Escondido, CA, United States of America

Gunars E Valkirs